Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
To read the full story
Related Article
- Chuikyo OKs Lagevrio, Voxzogo, Enjaymo, and More for August Listing, BioMarin Med with Biggest Peak Sales Outlook
August 10, 2022
- MHLW Panel Endorses Sanofi’s Sutimlimab as Japan’s First CAD Therapy
June 3, 2022
- Japan Panel OKs Taiho’s GIST Med, ViiV/Janssen’s HIV Combo and More for Approval
May 31, 2022
- Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
REGULATORY
- 12 Quasi-Original Drugs to Be Excluded from New Coverage Scheme
April 23, 2024
- Japan Wants to See Positive Trends on Drug Development after Reform: Official
April 23, 2024
- Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
April 23, 2024
- Japan Commences Project to Provide Telemedicine Services at Post Offices
April 22, 2024
- MHLW Proposes Simplified Generic Delisting Scheme
April 22, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…